Immunomodulation without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin

Stan Stoyanov, MD

VP Clinical Development

November 7, 2025

Forward-Looking Statements

The material in this presentation has been prepared by SAB Biotherapeutics, Inc., doing business as SAB BIO ("SAB") and is general background information about SAB's activities current as of the date of this presentation. This information is given in summary form and is not intended to be complete. Information in this presentation, including financial forecasts, should not be considered advice or a recommendation to investors or potential investors in relation to holding, purchasing, or selling securities or other financial products or instruments and does not take into account any particular investment objectives, financial situation or needs.

This presentation may contain forward-looking statements including statements regarding our intent, belief, or current expectations with respect to SAB's businesses and operations, market conditions, the exercise of outstanding warrants for cash, results of operations and financial condition, capital adequacy, specific provisions, and risk management practices. Readers are cautioned not to place undue reliance on these forward-looking statements. SAB does not undertake any obligation to update any information herein for any reason or to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events unless required by law. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner and the presentation may contain errors or omissions. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside SAB's control. Past performance is not a reliable indication of future performance. The forward-looking statements contained or implied in this presentation are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SAB's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") and in subsequent filings and reports that SAB makes with the SEC from time to time, including but not limited to SAB's Registration Statement on Form S-3 (File No. 333-289992) declared effective by the SEC on September 30, 2025, and the prospectus contained therein.

Unless otherwise specified, information is current at the date hereof. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

SAB-142 is a Fully Human, Multi-Specific, Targeted Anti-Thymocyte Globulin (hATG) for Delaying Onset and Progression of T1D

POTENTIAL DISEASE MODIFICATION

Lead candidate SAB-142 has the **potential to deliver disease modification in newly diagnosed Stage 3 T1D with convenient twice-yearly dosing,** supported by clinical data and a de-risked mechanism of action

POSITIVE PHASE 1 DATA SUPPORTS DE-RISKED MOA

Phase 1 data show SAB-142 has an MOA comparable to rabbit ATG, **with improved safety and potential for repeat dosing**, supporting advancement into the Phase 2b SAFEGUARD study

UNIQUE MULTI-SPECIFIC ANTIBODY PLATFORM

First-ever platform that can generate a diverse repertoire of **multi-specific, targeted, anti-thymocyte human IgG**

SAB BIO

SAB-142-101
Phase 1 Study Design

Randomized, double-blind, placebo-controlled, single- and multiple ascending dose, adaptive design clinical study in healthy volunteers and patients with established T1D

Total n=68 subjects Randomized:

HVs n=62
T1D patients n=6

Repeat dosing	n=8
4.5 mg/kg	n=8
2.5 mg/kg	N=22
1.5 mg/kg	n=8
0.5 mg/kg	n=16
0.1 mg/kg	n=8
0.03 mg/kg	n=6

SAB-142 demonstrated clinically validated multi-specific MOA with sustained immunomodulation

Safety & Tolerability — Data strongly position SAB-142 for potentially safe & reliable chronic dosing

- Does not cause lymphodepletion (no depletion of T-cells including Tregs, B cells, NK cells)
- Does not cause neutropenia, sustained decrease in RBCs or thrombocytes

PK/PD — Data demonstrate sustained "T-cell exhaustion" signature

- Clinically validated by rabbit ATG and other T1D T-cell targeting immunomodulatory drugs
- Proven to correlate with C-peptide preservation based on clinical studies in new onset T1D

No serum sickness & low/no immunogenicity — Data confirm SAB-142 is not immunogenic

- Does not cause serum sickness
- Does not induce anti-drug antibodies

SAB-142-101
Phase 1 Top Line

SAB-142 CD4+ T conv Cell Single Exhaustion Markers

SAB-142 induced sustained expression of inhibitory receptors (PD-1 and TIGIT) on CD4+ T conv cells indicative of an exhausted phenotype.

SAB-142: combined 1.5mg/kg and 2.5mg/kg dosed cohorts

SAB-142 CD4+ T conv Cell Dual Exhaustion Markers

SAB-142 induced sustained expression of co-inhibitory receptors on CD4+ T conv cells.

SAB-142: combined 1.5mg/kg and 2.5mg/kg dosed cohorts

Rabbit ATG CD4+ T Cell Dual Exhaustion Markers

Low-dose ATG induced sustained expression of co-inhibitory receptors (PD-1, KLRG1) on CD4+ cells indicating exhaustion-like phenotype which correlates with C-Peptide preservation.

SAB-142 demonstrates sustained CD4+ T conventional cell exhaustion analogous to rATG










JCI insight
CLINICAL MEDICINE

Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes

Laura M. Jacobsen,[1,2] Kirsten Diggins,[1] Lori Blanchfield,[1] James McNichols,[2] Daniel J. Perry,[2] Jason Brant,[2] Xiaoru Dong,[2,4] Rhonda Bacher,[4] Vivian H. Gersuk,[3] Desmond A. Schatz,[1] Mark A. Atkinson,[1,2] Clayton E. Mathews,[1,2] Michael J. Haller,[1] S. Alice Long,[3] Peter S. Linsley,[3] and Todd M. Brusko[1,2]

[1]Department of Pediatrics, College of Medicine, University of Florida, Gainesville, Florida, USA. [2]Department of Pathology, Immunology, and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, Florida, USA. [3]Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA. [4]Department of Biostatistics, University of Florida, Gainesville, Florida, USA.

SAB-142-101
Phase 1 Top Line

No sustained lymphodepletion

- SAB-142: Transient lymphopenia due to lymphocyte margination
- Lymphocytes recover back to baseline by Day 7

Rabbit ATG causes sustained lymphodepletion up to 2 years


JCI insight — CLINICAL MEDICINE

Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes

Laura M. Jacobsen,[1,2] Kirsten Diggins,[1] Lori Blanchfield,[1] James McNichols,[2] Daniel J. Perry,[2] Jason Brant,[2] Xiaoru Dong,[2,4] Rhonda Bacher,[4] Vivian H. Gersuk,[3] Desmond A. Schatz,[1] Mark A. Atkinson,[1,2] Clayton E. Mathews,[1,2] Michael J. Haller,[1] S. Alice Long,[3] Peter S. Linsley,[3] and Todd M. Brusko[1,2]

[1]Department of Pediatrics, College of Medicine, University of Florida, Gainesville, Florida, USA. [2]Department of Pathology, Immunology, and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, Florida, USA. [3]Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA. [4]Department of Biostatistics, University of Florida, Gainesville, Florida, USA.

SAB-142 does not cause sustained lymphodepletion





SAB-142-101
Phase 1 Top Line

No loss of CD4+ or CD8+ T Cells

- SAB-142 results in immunomodulation with no depletion of CD8⁺ or CD4⁺ T cells, including T regulatory cells
- SAB-142 demonstrated validated MOA to deliver potentially **Best-in-Class T1D immunotherapy**

Rabbit ATG causes sustained depletion of CD4⁺ T cells.


JCI insight — CLINICAL MEDICINE

Responders to low-dose ATG induce CD4⁺ T cell exhaustion in type 1 diabetes

Laura M. Jacobsen,[1,2] Kirsten Diggins,[3] Lori Blanchfield,[3] James McNichols,[2] Daniel J. Perry,[2] Jason Brant,[2] Xiaoru Dong,[2,4] Rhonda Bacher,[4] Vivian H. Gersuk,[3] Desmond A. Schatz,[1] Mark A. Atkinson,[1,2] Clayton E. Mathews,[1,2] Michael J. Haller,[1] S. Alice Long,[3] Peter S. Linsley,[3] and Todd M. Brusko[1,2]

[1]Department of Pediatrics, College of Medicine, University of Florida, Gainesville, Florida, USA. [2]Department of Pathology, Immunology, and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, Florida, USA. [3]Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA. [4]Department of Biostatistics, University of Florida, Gainesville, Florida, USA.

SAB-142 does not cause sustained lymphodepletion



No CD4⁺ T-cell lymphodepletion



No CD8⁺ T-cell lymphodepletion





SAB-142
In Vitro Data

SAB-142 and rabbit ATG (rATG) Binding and Activation of FcγRIII Pathway (ADCC), FcRn and FcγRI

SAB-142 has less binding to FcγRIII and less ADCC activation than rATG

Binding to the FcγRIII on natural killer cells activates cellular pathways leading to antibody dependent cellular cytotoxicity (ADCC)

No ADCC at therapeutic doses of SAB-142 → no lymphodepletion

Similar or better binding to FcRn and FcγRI facilitates immune activation & exhaustion

The human FcRn transports IgG across endothelial barriers; facilitates movement of IgG in both directions

The human FcγRI increases immune activation in multiple immune cell types

Competitive Inhibition of FcγRIIIa(V158) Binding



Condition	IC 50
rATG	2.46
SAB-142	16.39

ADCC Activation on Jurkat Cells



Condition	EC 50
rATG	0.35
SAB-142	3.57

Competitive Inhibition of FcRn Binding



Condition	IC 50
rATG	20.11
SAB-142	2.16

Competitive Inhibition of FcγRI Binding



Condition	IC 50
rATG	0.05
SAB-142	0.03

8

CONCLUSION

SafeGUARD
SAFety and Efficacy of Human Antithymocyte ImmunoGlobUlin
SAB-142 ARresting Progression of Type 1 Diabetes

ISPAD 2025
Montréal, Canada
51st Annual Conference November 5 - 8, 2025

SAB-142 demonstrated a validated MOA to deliver potentially Best-in-Class T1D immunotherapy

- Only transient lymphopenia due to margination was observed during dosing without sustained depletion of major blood cells
- SAB-142 has no ADCC activity at therapeutic concentrations

Phase 2 Clinical Trial SAFEGUARD has Launched

U.S., Australia, and New Zealand are approved with sites being initiated and submissions under review with EMA and MHRA.

SAB-142 data in depth at ISPAD

Nov 5th, 6th, and 7th, 2025

Profiling the Binding Specificities of SAB-142, a Fully Human Anti-Thymocyte Globulin, against T cell Surface Proteins

Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin

Mechanism of Action of a fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes

Specimen Quality for Multicenter Clinical Trials: Comparing Novel Blood Preservation Methods to Cryopreserved PBMC

Novel Pharmacokinetic (PK) Assay for Measuring SAB-142, a Fully Human Anti-Thymocyte Globulin

Safety Profile of SAB-142: A Fully Human Anti-Thymocyte Globulin
Friday, November 7th Poster Corner 2: Session Time: 15:15 - 16:15

SAB BIO